A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

Trial Profile

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2018

At a glance

  • Drugs Glycopyrrolate/indacaterol (Primary) ; Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms EXPEDITION; FLIGHT-1
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 23 May 2018 Results of pooled analysis of the FLIGHT1 and FLIGHT2 studies assessing impact of reversibility on lung function, health status, and dyspnea in COPD patients presented at the 114th International Conference of the American Thoracic Society
    • 23 May 2018 Results of pooled analysis of the FLIGHT1 and FLIGHT2 studies exploring the relationship between smoking status and clinical outcomes in COPD patients presented at the 114th International Conference of the American Thoracic Society
    • 16 May 2018 According to a Sunovion Pharmaceuticals media release, data from this study will be presented at the American Thoracic Society International Conference 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top